 RBC Capital raised the price target on Acadia Pharmaceuticals Inc NASDAQ:ACAD to 34 from 32 and kept an Outperform rating on the shares. Analyst Gregory Renza cites the Companys confirmed intentions to resubmit the sNDA filing of pimavanserin in Alzheimers Disease Psychosis, with a narrower though still robust opportunity as the largest subtype of DRP. 